Vienna Versus SARS-CoV-2 Virus Study
VIVI
1 other identifier
observational
12,000
1 country
1
Brief Summary
This study examines the seroprevalence against SARS-CoV-2 in health care workers and patients at the Vienna General Hospital.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2020
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 27, 2020
CompletedStudy Start
First participant enrolled
May 27, 2020
CompletedFirst Posted
Study publicly available on registry
May 29, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 27, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
June 27, 2021
CompletedMay 29, 2020
May 1, 2020
1.1 years
May 27, 2020
May 27, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Prevalence of antibody status in healthcare workers and in patients admitted for non-COVID-19 related symptoms over time
1 year
Secondary Outcomes (2)
Incidence rate of sero-conversion
1 year
Identification of risk markers/factors for SARS-CoV-2 infection
1 year
Study Arms (2)
Health care workers
Physicians, Nursing staff, Midwives, Medical-technical assistants (including medical, therapeutic and diagnostic healthcare staff, and medical and nursing assistants), administrative personnel with patient contact
Patients
Patients admitted for non-COVID related symptoms to the Vienna General Hospital with available residual serum samples.
Interventions
Storage of serum for SARS-CoV-2-antibodies and biomarkers
Eligibility Criteria
Cohort A: Health care workers Cohort B: Patients admitted for non-COVID related symptoms
You may qualify if:
- Physicians
- Nursing staff
- Midwives
- Medical-technical assistants (including medical, therapeutic and diagnostic healthcare staff, and medical and nursing assistants)
- Administrative personnel with patient contact
You may not qualify if:
- Not employed at the Medical University of Vienna or the Vienna General Hospital
- No signed informed consent
- Cohort B:
- ● Patients with available residual serum samples
- ● Serum samples from COVID-19 triage units at the Vienna General Hospital
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Medical University of Vienna
Vienna, 1090, Austria
Related Publications (1)
Riesenhuber M, Nitsche C, Binder CJ, Schernhammer ES, Stamm T, Jakse F, Anwari E, Hamidi F, Haslacher H, Perkmann T, Hengstenberg C, Zelniker TA. Comparison of the prevalence of SARS-CoV-2 nucleoprotein antibodies in healthcare workers and an unselected adult and paediatric all-comer patient population: insights from a longitudinal study of healthcare workers and concurrent serial cross-sectional studies of patients at an academic medical centre in Austria. BMJ Open. 2023 Jan 18;13(1):e063760. doi: 10.1136/bmjopen-2022-063760.
PMID: 36657754DERIVED
Biospecimen
Serum samples
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Christian Hengstenberg, Univ.-Prof.
Medical University of Vienna
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Univ.-Prof.
Study Record Dates
First Submitted
May 27, 2020
First Posted
May 29, 2020
Study Start
May 27, 2020
Primary Completion
June 27, 2021
Study Completion
June 27, 2021
Last Updated
May 29, 2020
Record last verified: 2020-05